1. Home
  2. MAIA vs XPL Comparison

MAIA vs XPL Comparison

Compare MAIA & XPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MAIA
  • XPL
  • Stock Information
  • Founded
  • MAIA 2018
  • XPL 1984
  • Country
  • MAIA United States
  • XPL United States
  • Employees
  • MAIA N/A
  • XPL N/A
  • Industry
  • MAIA Biotechnology: Pharmaceutical Preparations
  • XPL Precious Metals
  • Sector
  • MAIA Health Care
  • XPL Basic Materials
  • Exchange
  • MAIA Nasdaq
  • XPL Nasdaq
  • Market Cap
  • MAIA 46.7M
  • XPL 47.9M
  • IPO Year
  • MAIA 2022
  • XPL N/A
  • Fundamental
  • Price
  • MAIA $1.95
  • XPL $0.68
  • Analyst Decision
  • MAIA
  • XPL Strong Buy
  • Analyst Count
  • MAIA 0
  • XPL 2
  • Target Price
  • MAIA N/A
  • XPL $1.60
  • AVG Volume (30 Days)
  • MAIA 283.6K
  • XPL 175.3K
  • Earning Date
  • MAIA 05-09-2025
  • XPL 07-29-2025
  • Dividend Yield
  • MAIA N/A
  • XPL N/A
  • EPS Growth
  • MAIA N/A
  • XPL N/A
  • EPS
  • MAIA N/A
  • XPL N/A
  • Revenue
  • MAIA N/A
  • XPL N/A
  • Revenue This Year
  • MAIA N/A
  • XPL N/A
  • Revenue Next Year
  • MAIA N/A
  • XPL N/A
  • P/E Ratio
  • MAIA N/A
  • XPL N/A
  • Revenue Growth
  • MAIA N/A
  • XPL N/A
  • 52 Week Low
  • MAIA $1.40
  • XPL $0.54
  • 52 Week High
  • MAIA $4.31
  • XPL $0.98
  • Technical
  • Relative Strength Index (RSI)
  • MAIA 57.09
  • XPL 63.95
  • Support Level
  • MAIA $1.71
  • XPL $0.60
  • Resistance Level
  • MAIA $1.81
  • XPL $0.63
  • Average True Range (ATR)
  • MAIA 0.09
  • XPL 0.03
  • MACD
  • MAIA 0.00
  • XPL 0.01
  • Stochastic Oscillator
  • MAIA 70.59
  • XPL 86.36

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.

About XPL Solitario Resources Corp.

Solitario Resources Corp is exploration company engaging in acquiring, exploring, and developing zinc properties and other precious metals in safe jurisdictions in North and South America. It has joint venture interests in large, high-grade zinc development projects. The Florida Canyon Zinc Project in Peru is a development asset held jointly with Nexa Resources S.A., Golden Crest Project in South Dakota and the Lik Zinc Project represents a large-tonnage, high-grade development project in Alaska in partnership with Teck Resources. In addition, the company has an additional portfolio of exploration properties and royalties in the Americas.

Share on Social Networks: